Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Transnational Cannabis Ltd. (TRCNF)
Vancouver, BC, CA
Transnational Cannabis Ltd., through its various subsidiaries, operates within the cannabis sector both domestically in Canada and across international markets. The company holds the necessary licenses to undertake a comprehensive range of activities, including the cultivation, production, supply, storage, import, export, and transportation of cannabis and its derivative products. Furthermore, it is involved in the procurement and distribution of medical cannabis products and various cannabis derivatives. Transnational Cannabis has established strategic alliances with several key partners, notably Green Tree International Inc., Auxly Cannabis Group Inc., Affinity Alpha Unit, Authentic Brands Group, and Biotii Technologies Corp. The company was previously known as ICC International Cannabis Corp. before officially renaming itself TRANSNATIONAL CANNABIS LTD in February 2020. Founded in 2006, its corporate headquarters are situated in Vancouver, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -96.00% | -96.00% | +3,900.00% | -96.00% | -60.00% | -99.27% | -99.99% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-522.9% Q4'19: +24.1% (vs Q4'18)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-88.5% Q4'19: -117.5% (vs Q4'18)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+887.0% Q4'19: +231.3% (vs Q4'18)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.13× Q4'19: -2.94× (vs Q4'18)
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Shpilt | Chief Executive Officer | — | male |
| Lauren Magda | Chief of Staff | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRCNF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
